Efficacy and toxicity of PARP inhibitor in elderly patients with homologous recombination-deficient newly diagnosed advanced ovarian cancer: the role of dose modification.

Abstract excerpt

OBJECTIVE: To investigate the impact of age on the progression-free survival (PFS) and dose modification, discontinuation and adverse events of poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) maintenance therapy in homologous recombination-deficient (HRD) ovarian cancer patients. METHODS: We analyzed 324 patients with advanced stage III-IV epithelial ovarian cancer who had either BRCA mutation or...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Age Factors
• Share to Carcinoma, Ovarian Epithelial